Open AccessGlutathione triggered degradation of polydopamine to facilitate controlled drug release for synergic combinational cancer treatment
Author(s) -
Yanan Hao,
Anqi Zheng,
Tingting Guo,
Yang Shu,
Jianhua Wang,
Omar Johnson,
Wei Chen
Publication year - 2019
Publication title -
journal of materials chemistry. b
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.316
H-Index - 101
eISSN - 2050-7518
pISSN - 2050-750X
DOI - 10.1039/c9tb01400d
Subject(s) - glutathione , degradation (telecommunications) , drug , cancer drugs , cancer , materials science , pharmacology , chemistry , combinatorial chemistry , medicine , biochemistry , computer science , enzyme , telecommunications
Here we report a novel mechanism for triggering drug release in the polydopamine (PDA)-coated magnetic CuCo 2 S 4 core-shell nanostructure by glutathione (GSH) triggered degradation of PDA for release. In the design, we used PDA coated CuCo 2 S 4 as the nanocarrier with polyethylene glycol and folic acid targeting molecules to ensure the safe delivery of doxorubicin (DOX) to cancer cells. In addition, the controlled release could be enforced by taking advantage of the pH sensitivity of PDA to tumor acidic environments. The targeting and treatment of HeLa cancer cells were very effective and the killing was more efficient at higher levels of GSH. Furthermore, the designed system not only could be used for drug delivery but also could combine photothermal therapy with chemotherapy in a synergetic way. Plus, the system could be used for magnetic resonance imaging (MRI), which is beneficial for imaging-guided treatment.